Skip to main content

Latest oncology news

21-05-2019 | Oncology | News | Article

No benefit with nintedanib in advanced malignant pleural mesothelioma

Adding nintedanib to pemetrexed plus cisplatin does not improve progression-free survival for patients with advanced malignant pleural mesothelioma, say researchers who conducted a phase III trial on the basis of earlier positive findings.

20-05-2019 | Oncology | News | Article

Poor glycemic control linked to prostate cancer progression

In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.

17-05-2019 | Oncology | News | Article

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

17-05-2019 | Oncology | News | Article

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

16-05-2019 | Oncology | News | Article

Immunotherapy response differs by EFGR mutation subtype

The response to treatment with immune checkpoint inhibitors varies according to EGFR mutant subtype in patients with non-small-cell lung cancer, US researchers report.

14-05-2019 | Oncology | News | Article

Whole-body MRI staging quicker and cheaper than standard pathways in NSCLC

The Streamline L trial has found that in patients with newly diagnosed non-small-cell lung cancer, a staging pathway using whole-body magnetic resonance imaging has similar accuracy but a shorter time to complete staging and lower mean per-patient costs versus standard pathways.

13-05-2019 | Oncology | News | Article

Local consolidative therapy improves oligometastatic NSCLC survival

Patients with stage IV non-small-cell lung cancer and no more than three metastases derive an overall survival benefit from aggressive local consolidative therapy, suggest trial results.

10-05-2019 | Oncology | News | Article

ctDNA predicts relapse and response in bladder cancer

Ultra-deep sequencing of circulating tumor DNA is highly sensitive and specific for early risk stratification in patients with bladder cancer, predicting treatment response and identifying patients with early metastatic relapse, indicate findings reported in the Journal of Clinical Oncology.

09-05-2019 | Oncology | News | Article

5α-reductase inhibitors linked to elevated prostate cancer death rates

Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.

08-05-2019 | Oncology | News | Article

KEYNOTE-045: Pembrolizumab benefit maintained over 2 years in urothelial cancer

Patients with advanced urothelial cancer continue to derive a significant overall survival benefit with second-line pembrolizumab over chemotherapy, indicates an analysis of KEYNOTE-045 with more than 2 years of follow-up.

07-05-2019 | Oncology | News | Article

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

03-05-2019 | Oncology | News | Article

Biosimilar pegfilgrastim receives EMA go-ahead, generic cabazitaxel does not

Read more on these announcements here

03-05-2019 | Oncology | News | Article

Mesothelioma survival doubles with radical hemi-thoracic radiotherapy regimen

Switching palliative radiation for high-dose radical hemi-thoracic radiotherapy significantly increases 2-year overall survival among patients with a new diagnosis of malignant pleural mesothelioma, delegates were told at the ESTRO 38 meeting in Milan, Italy.

02-05-2019 | Prostate cancer | News | Article

Single HDR brachytherapy treatment effective for low-risk prostate cancer

A single dose of high-dose rate brachytherapy prevents biochemical recurrence for at least 3 years in patients with low-risk prostate cancer, but is less effective among those with higher-risk disease, researchers report.

02-05-2019 | Oncology | News | Article

Biologic, genetic markers predict radiation toxicity in oncology patients

A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.

30-04-2019 | Oncology | News | Article

Clinicogenomic database yields clinically relevant insights in NSCLC

US researchers have replicated previously described associations between patient and tumor characteristics and clinical outcomes using routinely collected clinical and genomic data for patients with non-small-cell lung cancer.

29-04-2019 | Lung cancer | News | Article

ALESIA backs first-line alectinib in Asian NSCLC patients

Previously untreated Asian patients with advanced ALK translocation-positive non-small-cell lung cancer derive a significant progression-free survival benefit from alectinib over crizotinib, indicate phase III trial results.

29-04-2019 | Oncology | News | Article

FDA approves first-line pembrolizumab–axitinib for advanced RCC

Click through to read more

26-04-2019 | Oncology | News | Article

Crizotinib offers long-term benefits in ROS1-rearranged advanced NSCLC

Crizotinib provides durable clinical benefit to patients with ROS1-rearranged advanced non-small-cell lung cancer, show updated PROFILE 1001 data.

26-04-2019 | Oncology | News | Article

Erdafitinib Approved For Advanced Urothelial Carcinoma

Read more on this FDA announcement here

Image Credits